One of the main challenges in targeting aggregation is the complexity of the tumor microenvironment and the redundancy in the pathways involved in cell aggregation. Cancer cells can adapt to therapeutic pressures and find alternative ways to aggregate and survive. Moreover, disrupting aggregation without affecting normal tissues and physiological processes is a significant challenge. Therefore, a deeper understanding of the specific mechanisms driving aggregation in different cancer types is essential for developing effective therapies.
